Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11 Thoracic 8 Gastrointestinal 5 CNS 2 Tumor-Agnostic 1 Other solid neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 94 Paclitaxel 85 Gemcitabine 83 Carboplatin 79 Docetaxel 60 Cisplatin 58 Bevacizumab 58 Nivolumab 56 Fluorouracil 47 Capecitabine 46 Magnetic Resonance Spectroscopy 44 Radiotherapy 41 Irinotecan 40 Oxaliplatin 38 Erlotinib Hydrochloride 37 Pemetrexed 34 Leucovorin 34 Biopsy 34 atezolizumab 33 Cetuximab 32 Standard of Care 31 Trastuzumab 28 Cyclophosphamide 28 Radiosurgery 27 Blood Specimen Collection 27 Specimen Handling 26 Sorafenib 26 Ipilimumab 26 Everolimus 26 olaparib 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × patritumab deruxtecan × Tumor-Agnostic × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡